Headlines about Clorox (NYSE:CLX) have trended somewhat positive recently, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Clorox earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.3176443559411 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news articles that may have effected Accern’s scoring:

A number of research analysts have recently commented on CLX shares. Jefferies Group reiterated a “hold” rating and set a $132.00 target price (down from $137.00) on shares of Clorox in a research report on Friday, October 6th. Zacks Investment Research downgraded Clorox from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Morgan Stanley lowered their target price on Clorox from $138.00 to $128.00 and set an “equal weight” rating for the company in a research report on Thursday, November 2nd. Consumer Edge upgraded Clorox from a “neutral” rating to an “outperform” rating in a research report on Friday, November 10th. Finally, Wells Fargo & Co increased their target price on Clorox from $130.00 to $146.00 and gave the company a “market perform” rating in a research report on Thursday, January 4th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $134.33.

Clorox (CLX) traded down $2.44 during trading hours on Thursday, reaching $141.99. The company had a trading volume of 1,192,200 shares, compared to its average volume of 777,451. Clorox has a one year low of $118.41 and a one year high of $150.40. The stock has a market cap of $18,310.00, a price-to-earnings ratio of 26.05, a PEG ratio of 3.84 and a beta of 0.42. The company has a quick ratio of 0.77, a current ratio of 1.10 and a debt-to-equity ratio of 3.02.

Clorox (NYSE:CLX) last released its quarterly earnings results on Wednesday, November 1st. The company reported $1.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.41 by $0.05. Clorox had a return on equity of 161.59% and a net margin of 11.84%. The company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.48 billion. During the same quarter in the prior year, the firm posted $1.36 EPS. Clorox’s quarterly revenue was up 4.0% compared to the same quarter last year. analysts anticipate that Clorox will post 5.66 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, February 9th. Investors of record on Wednesday, January 24th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, January 23rd. This represents a $3.36 annualized dividend and a yield of 2.37%. Clorox’s payout ratio is presently 61.65%.

In related news, SVP Matthew T. Laszlo sold 20,051 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $130.46, for a total transaction of $2,615,853.46. Following the sale, the senior vice president now owns 10,896 shares in the company, valued at approximately $1,421,492.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael R. Costello sold 10,574 shares of the stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $136.01, for a total value of $1,438,169.74. Following the sale, the senior vice president now owns 34,867 shares in the company, valued at approximately $4,742,260.67. The disclosure for this sale can be found here. Corporate insiders own 1.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-clorox-clx-stock-price/1803460.html.

About Clorox

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Insider Buying and Selling by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with Analyst Ratings Network's FREE daily email newsletter.